GSWM
CRBP icon

Golden State Wealth Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Golden State Wealth Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$685 Hold
73
– – ﹤0.01% 1516
2026
Q1 		$685 Hold
73
– – ﹤0.01% 1489
2025
Q4 		$594 Hold
73
– – ﹤0.01% 1580
2025
Q3 		$923 Hold
73
– – ﹤0.01% 1514
2025
Q2 		$504 Hold
73
– – ﹤0.01% 1496
2025
Q1 		$388 Hold
73
– – ﹤0.01% 1520
2024
Q4 		$861 Buy
+73
New +$1.22K ﹤0.01% 1373

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Golden State Wealth Management's CRBP Position: Q2 2026 in Review

Golden State Wealth Management held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 73 shares worth $685. The position accounts for ﹤0.01% of the portfolio, ranked #1516.

Golden State Wealth Management first reported a position in CRBP in Q4 2024 and has held it in 7 quarters since. The position peaked at $923 in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Golden State Wealth Management held 73 shares of Corbus Pharmaceuticals worth $685 as of Q2 2026.
  • Golden State Wealth Management left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1516 holding.
  • Golden State Wealth Management first reported a position in Corbus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Golden State Wealth Management's Corbus Pharmaceuticals position peaked at $923 in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.